Temozolomide & Pazopanib Hydrochloride in Treating Patients With Advanced

Status Completed

Clinical Trial Summary

This phase I/II trial studies the side effects and best dose of temozolomide and pazopanib hydrochloride when given together and to see how well they work in treating patients with advanced pancreatic neuroendocrine tumors (PNET) that cannot be removed by surgery. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for tumor growth. Giving temozolomide together with pazopanib hydrochloride may be an effective treatment for patients with PNET.

Clinical Trial Description

PRIMARY OBJECTIVES: I. Determine the maximum tolerated dose (MTD) of temozolomide and pazopanib (pazopanib hydrochloride) combination in patients with advanced PNET. (Phase I) II. Determine the overall response rate (ORR). (Phase II) SECONDARY OBJECTIVES: I. Determine safety and toxicity profile of the combination of temozolomide and pazopanib in this population. (Phase I) II. Describe the pharmacokinetics of temozolomide alone and in combination with pazopanib. (Phase I) III. Observe the ORR. (Phase I) IV. Determine progression-free survival (PFS) and overall survival (OS), disease control rate (DCR), and duration of response (DOR). (Phase II) V. Determine the safety and toxicity profile of the combination in a larger cohort of patients. (Phase II) TERTIARY OBJECTIVES: I. Examine the relationship between tumor blood flow, as measured by perfusion functional computed tomography (f CT), and overall response. II. Correlate the expression of tissue methyl-guanine methyl transferase (MGMT) as measured by immunohistochemistry (IHC) with ORR and PFS. OUTLINE: This is a phase I, dose-escalation study followed by a phase II study. Patients receive temozolomide orally (PO) once daily (QD) on days 1-7 and 15-21 and pazopanib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 3 months. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01465659
Study type	Interventional
Source	Northwestern University
Contact
Status	Completed
Phase	Phase 1/Phase 2
Start date	December 12, 2011
Completion date	January 27, 2021

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT02108782` - Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors	Phase 2
Terminated	`NCT02273752` - Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer	Phase 2
Terminated	`NCT00084461` - Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors	Phase 2
Completed	`NCT01155258` - Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors	Phase 1
Completed	`NCT00131911` - Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors	Phase 2
Completed	`NCT01525082` - Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors	Phase 2
Completed	`NCT00655655` - Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors	Phase 1
Completed	`NCT00075439` - Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors	Phase 2
Completed	`NCT00093782` - Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma	Phase 2
Active, not recruiting	`NCT01824875` - Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors	Phase 2
Completed	`NCT00004074` - Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu	Phase 1
Completed	`NCT02259725` - Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors	Phase 2
Terminated	`NCT02031536` - Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms